Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People with advanced or spreading non-small cell lung cancer (a type of lung cancer) for whom a specific type of immunotherapy — called PD-1/PD-L1 therapy — is approved as a first treatment, either on its own or combined with other treatments (Group A).
• People with advanced or spreading non-small cell lung cancer who have finished up to 4 rounds of initial treatment and whose cancer has stayed stable or responded well, and for whom PD-1/PD-L1 immunotherapy is approved as an ongoing maintenance treatment (Group B).
• People with advanced or spreading solid tumour cancers (not limited to lung cancer) for whom PD-1/PD-L1 immunotherapy is approved as a first treatment, either alone or in combination (Group C).
• People who have not previously received this type of immunotherapy (Groups A and C), or who received it as an initial treatment and are now moving to a maintenance phase (Group B).
• People who are willing to be randomly assigned to take their treatment either early in the morning or later in the day or evening.
• People for whom a treating doctor determines that PD-1/PD-L1 immunotherapy is appropriate under standard care guidelines and approved uses.
• People who are able to understand and willing to sign a written consent form.
• People who are able to read and write in English.

Who may not be able to join:

• People who cannot receive PD-1/PD-L1 immunotherapy because of a previous allergic reaction to that treatment or any of its ingredients.

Important: Always verify eligibility with the trial site directly before applying.